Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery

Ikuta, Shinichi; Tanimura, Kiyoko; Yasui, Chiaki; Aihara, Tsukasa; Yoshie, Hidenori; Iida, Hiroya; Beppu, Naohito; Kurimoto, Ami; Yanagi, Hidenori; Mitsunobu, Masao; Yamanaka, Naoaki

doi:10.1007/s10156-010-0188-8

Cited by 55 publications

(44 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ethical approval: This study was approved by the Ethics Review Board of Kagoshima University Hospital (Kagoshima, Japan) [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]. Written informed consent was obtained from 44 adult patients included in the study.…”

Section: Tablementioning

confidence: 99%

“…Several studies reported that the incidence of linezolid-induced thrombocytopenia was high (7.5-64.7%) [4,[7][8][9][10][11][12][13][14][15]. Risk factors for the development of thrombocytopenia during linezolid therapy include impaired renal function [7,8,10,11,[16][17][18][19][20], chronic liver disease [20,21], the duration of linezolid therapy (≥14 days) [6,7] and respiratory tract infection [7]. Furthermore, recent studies reported that the incidence of linezolid-induced thrombocytopenia was significantly higher in patients with impaired renal function than in patients with normal renal function [7,8,16,17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients

Matsumoto

Shigemi

Takeshita

et al. 2014

International Journal of Antimicrobial Agents

118

121

View full text Add to dashboard Cite

Section: Tablementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients

Matsumoto

Shigemi

Takeshita

et al. 2014

International Journal of Antimicrobial Agents

118

121

View full text Add to dashboard Cite

“…These disorders are also associated with increased risk of serious infections, including those due to drug-resistant Gram-positive pathogens (10,12,13), and clinically significant adverse effects caused by antibacterial treatment itself (10,14,15). Because of aging populations, the prevalences of chronic kidney disease (16) and chronic liver disease (17) are increasing.…”

mentioning

confidence: 99%

Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment

Flanagan

Minassian

Morris

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Two open-label, single-dose, parallel-group studies were conducted to characterize the pharmacokinetics of the novel antibacterial tedizolid and the safety of tedizolid phosphate, its prodrug, in renally or hepatically impaired subjects. Tedizolid pharmacokinetics in subjects with severe renal impairment without dialysis support was compared with that of matched control subjects with normal renal function. Effects of hemodialysis on tedizolid pharmacokinetics were determined in a separate cohort of subjects undergoing long-term hemodialysis. Effects of hepatic impairment on tedizolid pharmacokinetics were determined in subjects with moderate or severe hepatic impairment and compared with those of matched control subjects with normal hepatic function. Each participant received a single oral (hepatic impairment) or intravenous (renal impairment) dose of tedizolid phosphate at 200 mg; hemodialysis subjects received two doses (separated by 7 days), before and after dialysis, in a crossover fashion. The pharmacokinetics of tedizolid was similar in subjects with severe renal impairment and controls (ϳ8% lower area under the concentration-time curve [AUC], with a nearly identical peak concentration) and in subjects undergoing hemodialysis before and after tedizolid phosphate administration (ϳ9% lower AUC, with a 15% higher peak concentration); <10% of the dose was removed during 4 h of hemodialysis. Tedizolid pharmacokinetics was only minimally altered in subjects with moderate or severe hepatic impairment; the AUC was increased approximately 22% and 34%, respectively, compared with that of subjects in the control group. Tedizolid phosphate was generally well tolerated in all participants. These results suggest that tedizolid phosphate dose adjustments are not necessary in patients with any degree of renal or hepatic impairment. (This study has been registered at ClinicalTrials.gov under registration numbers NCT01452828 [renal study] and NCT01431833 [hepatic study].)

show abstract

“…The authors hypothesized that hepatic insufficiency increased the risk for hyperlactemia and likewise parallels Case 3 in the current communication. Hepatic dysfunction has also been implicated in thrombocytopenia development while receiving linezolid, another adverse effect of long-term administration 8 . Moreover, renal insufficiency has also been implicated in delayed linezolid clearance 9 , and may have influenced toxicity onset in our patients as all had elevated serum creatinine.…”

Section: Discussionmentioning

confidence: 99%

Linezolid and Lactic Acidosis

Su¹,

Crowley²,

Carcillo³

et al. 2011

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Linezolid administration has been associated with lactic acidosis in adults; however, the same phenomenon has not been reported in children. Mitochondrial protein synthesis inhibition is a demonstrated mechanism for toxicity, which therefore may manifest as lactic acidosis. Three cases of linezolid associated lactic acidosis in children are reported to reinforce the need for pediatric caregivers to be vigilant of this potential side effect.

show abstract

Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery

Cited by 55 publications

References 11 publications

Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients

Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients

Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment

Linezolid and Lactic Acidosis

Contact Info

Product

Resources

About